The FDA has spent the past several months evaluating reports of suicidal thoughts and actions reported via the agency’s adverse event reporting system and determined that the reports did not indicate a clear connection to the drugs, underscoring that the data provided are limited and can be influenced by other factors. Similarly, the agency’s review of clinical trials of GLP-1s did not find a link between the drugs and suicidal thoughts and actions.
“However, because of the small number of suicidal thoughts or actions observed in both people using GLP-1 RAs and in the comparative control groups, we cannot definitively rule out that a small risk may exist; therefore, FDA is continuing to look into this issue,” FDA wrote.
The FDA’s conclusion comes after an NIH-funded study published in Nature Medicine earlier this month found that semaglutide carried a lower risk of suicidal ideations compared to other non-GLP-1 obesity medications. A Novo Nordisk spokesperson told Endpoints News at the time that the company will continue to monitor reports of adverse reactions related to Ozempic and Wegovy, including suicidal ideation.
The FDA said it’s continuing to evaluate data further, including a meta-analysis of all clinical trials for GLP-1s and an analysis of post-marketing data in its Sentinel System, which collects large amounts of health data.
Leerink analysts noted that the FDA hasn’t given a timeline for when it will give another update. Meanwhile the European Medicines Agency’s safety committee is still reviewing the data around GLP-1s and the risk of suicidal thoughts and is slated to reconvene in April to discuss further.
The FDA underscores that patients should not stop taking GLP-1s before consulting their doctors and that healthcare professionals should continue monitoring and reporting instances of suicidal thoughts or actions associated with GLP-1s.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE
